Table 2.
Logistic regression analysis of baseline parameters and PSA Response
| Parameter | Univariate logistic regression, OR (95%CI) |
p-value | Multiple logistic regression, OR (95%CI) |
p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PSMA-ligand PET parameters | ||||||||||
| Number of lesions | 0.95 [0.8–1.15] | 0.611 | ||||||||
| TTV | 1.02 [0.89–1.16] | 0.802 | ||||||||
| ITLV | 1.05 [0.92–1.19] | 0.488 | ||||||||
| Highest SUVmax | 1.85 [1.33–2.62] | < 0.001 | ||||||||
| Whole-body SUVmax | 2.80 [1.83–4.48] | < 0.001 | 3.26 [2.01–5.55] | < 0.001 | ||||||
| Whole-body SUVmean | 3.96 [2.0-8.33] | < 0.001 | ||||||||
| Whole-body SUVpeak | 2.65 [1.71–4.25] | < 0.001 | ||||||||
| Pretherapeutic clinical parameters | ||||||||||
| Age | 1.04 [1.0-1.08] | 0.035 | 1.0 [0.95–1.06] | 0.987 | ||||||
| Time since initial diagnosis | 1.38 [1.03–1.87] | 0.034 | 1.31 [0.9–1.94] | 0.166 | ||||||
| Prior chemotherapy | 0.33 [0.17–0.64] | 0.001 | 0.3 [0.12–0.72] | 0.008 | ||||||
| Liver metastases | 1.12 [0.32–3.49] | 0.855 | ||||||||
| Visceral metastases | 0.95 [0.44-2.0] | 0.890 | ||||||||
| PSA | 1.02 [0.90–1.15] | 0.810 | ||||||||
| AP | 0.78 [0.58–1.03] | 0.091 | ||||||||
| LDH | 0.57 [0.31–0.93] | 0.039 | 0.79 [0.42–1.37] | 0.435 | ||||||
| Hb | 1.15 [0.98–1.37] | 0.094 | ||||||||
All continuous parameters except age and Hb were log (base2) transformed. Significant p-values are given in bold. PSA = prostate-specific antigen; OR = odds ratio; CI = confidence interval; PSMA = prostatespecific membrane antigen; PET = positron emission tomography; TTV = total tumor volume; ITLV = intensity-weighted lesion volume; SUVmax = maximum standardized uptake value; SUVmean = mean standardized uptake value; SUVpeak = peak standardized uptake value; AP = alkaline phosphatase; LDH = lactate dehydrogenase; Hb = hemoglobin